NIH VideoCast - From Mechanisms to Medicines: Realizing the DREAM of an Alzheimer's Cure

Skip Navigation

From Mechanisms to Medicines: Realizing the DREAM of an Alzheimer's Cure

Loading... Loading video...

507 Views

Air date:	Friday, September 18, 2020, 12:00:00 PM Time displayed is Eastern Time, Washington DC Local
Views:	Total views: 507 (266 Live, 241 On-demand)
Category:	NIH Director's Seminars
Runtime:	00:46:29
Closed captioning:	Check box to display CC outside of the video Note: You can drag the captioning window around and resize it
Description:	NIH Director's Seminar Series The repeated failures of disease-modifying treatments for Alzheimer’s disease (AD) have increased the urgency to identify novel therapeutic targets and biomarkers for AD and related dementias (ADRD). Dr. Thambisetty's Clinical and Translational Neuroscience Section has applied a systems biology approach leveraging deep molecular phenotyping by multi-OMICs methods in brain and blood in combination with multi-modal neuroimaging and epidemiological analyses to identify abnormal metabolic pathways in ADRD associated with severity of pathology and expression of clinical symptoms. These studies have added to a growing body of evidence that AD is a pervasive metabolic disorder with dysregulation in multiple interacting pathways. Dr. Thambisetty's findings have uncovered plausible therapeutic targets for ADRD from these dysregulated metabolic pathways. The Clinical and Translational Neuroscience Section has used large chemi-informatics databases to identify drugs that target genetic regulators of these pathways and have nominated several commonly used FDA-approved drugs as candidate AD treatments. Dr. Thambisetty's lab has initiated analyses to test whether exposure to these drugs in large real-world clinical datasets containing >20 million older individuals is associated with altered risk of incident AD/dementia in the Drug Repurposing for Effective Alzheimer’s Medicines (DREAM) study.

NLM Title:	From mechanisms to medicines : realizing the DREAM of an Alzheimer's cure / Madhav Thambisetty.
Author:	Thambisetty, Madhav. National Institutes of Health (U.S.),
Publisher:
Abstract:	(CIT): NIH Director's Seminar SeriesThe repeated failures of disease-modifying treatments for Alzheimer's disease (AD) have increased the urgency to identify novel therapeutic targets and biomarkers for AD and related dementias (ADRD). Dr. Thambisetty's Clinical and Translational Neuroscience Section has applied a systems biology approach leveraging deep molecular phenotyping by multi-OMICs methods in brain and blood in combination with multi-modal neuroimaging and epidemiological analyses to identify abnormal metabolic pathways in ADRD associated with severity of pathology and expression of clinical symptoms. These studies have added to a growing body of evidence that AD is a pervasive metabolic disorder with dysregulation in multiple interacting pathways. Dr. Thambisetty's findings have uncovered plausible therapeutic targets for ADRD from these dysregulated metabolic pathways. The Clinical and Translational Neuroscience Section has used large chemi-informatics databases to identify drugs that target genetic regulators of these pathways and have nominated several commonly used FDA-approved drugs as candidate AD treatments. Dr. Thambisetty's lab has initiated analyses to test whether exposure to these drugs in large real-world clinical datasets containing 20 million older individuals is associated with altered risk of incident AD/dementia in the Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study.
Subjects:	Alzheimer Disease--drug therapy Alzheimer Disease--genetics Alzheimer Disease--metabolism Drug Discovery Drug Repositioning Proteomics
Publication Types:	Lecture Webcast

NLM Classification:	WT 157
NLM ID:	101772202
CIT Live ID:	38520
Permanent link:	https://videocast.nih.gov/watch=38520

Related Videos...